The University of Toledo

American Hospital Supply Corporation

Schering Aktiengesellschaft

E.i. Dupont De Nemours and Company

Berlex Laboratories, Inc.

United States of America, As Represented by the Secretary of Agriculture

Xavier University of Louisiana

Paul W Erhardt

Bruce E Heck

Dong Hyun Kim

Brian Kress

William L Matier

Robert J Borgman

Alfred A Hagedorn, Iii

John P O'Donnell

Christopher J Trabbic

William A Maltese

John W Lampe

Chandrabose Karthikeyan

Amit K Tiwari

Haneen A Amawi

Piyush Trivedi

Jean H Overmeyer

William C Lumma, Jr

Ronald A Wohl

Kenneth Jay Shaw

Sheung-tsam Kam

Rahul Khupse

Wieslaw A Klis

Raju Mohan

Ghanshyam Patil

Thomas K Morgan, Jr

Matthew E Burow

Stephen M Boue

Yuo-Ling Chou

Thomas E Cleveland

Thomas E Wiese

John A McLachlan

Jay R Wiggins

Lumma, Jr, William C

Jefferey G Sarver

Ron H Bihovsky

Chi Woo

Stephan M Patrick

Amarjit Luniwal

Jeffery G Sarver

Moustafa M Aouthmany

Zehui Li

Michael W Robinson

Compounds, compositions, and methods useful for inducing cancer cell death via methuosis, autophagy, or a combination thereof, are described. The compounds have a 4-pyridyl group linked by a heterocyclic group to an aryl, heteroaryl, aralkyl, or heteroaryl alkyl.

Materials and methods useful to induce cancer cell death via methuosis or autophagy or a combination thereof

Peroxisome proliferator activated receptor (PPAR) compounds, and methods of using the same for treating bone fractures, treating osteoporosis and/or metabolic bone diseases, and inducing osteogenesis and/or chondrogenesis, are disclosed.

Proxisome proliferator activated receptor (PPAR) compounds and methods of using the same

Vacuole- or exosome-inducing indole-based chalcone and substituted triazole-hydrazone compounds that induce endosomal vacuolization and increase exosome yield, but do not trigger growth arrest or cell death, and methods of making and using are described.

Vacuole-inducing compounds, methods of making and using the same

Analogs of proxisome proliferator activated receptor (PPAR) agonists and methods of using the same

Compositions and methods for inhibiting the DNA repair protein complex, ERCC1-XPF, and methods to enhance clinical responses to anticancer drugs that interact with DNA such as cisplatin, and to overcome drug resistance due to DNA repair mechanisms, are described.

Inhibitors of ERCC1-XPF and methods of using the same

Analogs of PPAR5 and analogs of 20-OH-PGE2, which are PPAR5 agonists and 20-OH-PGE2 antagonists, respectively, and methods of using the same for inducing osteogenesis or chondrogenesis, are disclosed.

Analogs of peroxisome proliferator activated receptor (PPAR) agonists, and methods of using the same

The present invention provides materials and methods to induce cell death by methuosis, a non-apoptotic cell death mechanism, to induce vacuolization without cell death, or to induce cell death without vacuolization. Small molecules herein are useful for treating cell proliferation disorders or anomalies, particularly, but not exclusively, cancer. Methods related to the research and pharmaceutical use of the small molecules are also provided herein.

Materials and methods useful to induce vacuolization, cell death, or a combination thereof

The present invention provides materials and methods to induce cell death by methuosis, a non-apoptotic cell death mechanism. Small molecules herein are useful for treating cell proliferation disorders or anomalies, particularly, but not exclusively, cancer. Methods related to the research and pharmaceutical use of the small molecules are also provided herein.

Materials and methods useful to induce cell death via methuosis

Materials and Methods Useful to Induce Vacuolization, Cell Death, or a Combination Thereof

Growing community of inventors

Toledo, OH, United States of America

Paul W Erhardt